Matteo Della Porta, MD, IRCCS Humanitas Research Hospital, Milan, Italy, comments on the potential of artificial intelligence (AI) in improving patient management in myelodysplastic syndromes (MDS). He highlights that AI can help clinicians make more effective therapeutic decisions at an individual patient level, and mentions the development of a decision support system to optimize the timing of transplantation in MDS. This interview took place at the 13th Annual Meeting of the Society of Hematologic Oncology (SOHO 2025) in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.